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AbstrAct
Objective
To evaluate the diagnosis of myocardial infarction 
using a high sensitivity troponin I assay and sex 
specific diagnostic thresholds in men and women with 
suspected acute coronary syndrome.
Design
Prospective cohort study.
setting
Regional cardiac centre, United Kingdom.
ParticiPants
Consecutive patients with suspected acute coronary 
syndrome (n = 1126, 46% women). Two cardiologists 
independently adjudicated the diagnosis of myocardial 
infarction by using a high sensitivity troponin I assay 
with sex specific diagnostic thresholds (men 34 ng/L, 
women 16 ng/L) and compared with current practice 
where a contemporary assay (50 ng/L, single 
threshold) was used to guide care.
Main OutcOMe Measure
Diagnosis of myocardial infarction.
results
The high sensitivity troponin I assay noticeably 
increased the diagnosis of myocardial infarction in 
women (from 11% to 22%; P < 0.001) but had a minimal 
effect in men (from 19% to 21%, P = 0.002). Women 
were less likely than men to be referred to a 
cardiologist or undergo coronary revascularisation 
(P < 0.05 for both). At 12 months, women with 
undisclosed increases in troponin concentration 
(17–49 ng/L) and those with myocardial infarction 
(≥50 ng/L) had the highest rate of death or reinfarction 
compared with women without (≤16 ng/L) myocardial 
infarction (25%, 24%, and 4%, respectively; 
P < 0.001).
cOnclusiOns
Although having little effect in men, a high sensitivity 
troponin assay with sex specific diagnostic thresholds 
may double the diagnosis of myocardial infarction in 
women and identify those at high risk of reinfarction 
and death. Whether use of sex specific diagnostic 
thresholds will improve outcomes and tackle 
inequalities in the treatment of women with suspected 
acute coronary syndrome requires urgent attention.
Introduction
Major inequalities exist between men and women in the 
treatment and outcome of acute coronary syndromes, 
with an increase in both early and late deaths in 
women.1–3 Importantly, women with suspected acute 
coronary syndrome are less likely to have a diagnosis of 
myocardial infarction, an observation previously 
attributed to atypical symptoms and less reliable find-
ings on electrocardiography.4 5
The universal definition of myocardial infarction 
advocates the use of cardiac troponin assays, with an 
increase above the upper reference limit (derived from 
the 99th centile of a normal reference population) 
diagnostic of myocardial infarction in patients with 
symptoms or signs of myocardial ischaemia.6 Although 
the universal definition of myocardial infarction advo-
cates the 99th centile as the upper reference limit, only 
one in three clinical laboratories currently use this as 
the diagnostic threshold, given the analytical impreci-
sion of established troponin assays.7 More sensitive 
troponin assays improve the diagnosis of myocardial 
infarction,8 and use of these assays has been associ-
ated with reductions in recurrent myocardial infarc-
tion and death.9 10
One of the major advances of high sensitivity assays 
over contemporary assays is that troponin concentra-
tions can be quantified in most healthy people. These 
assays have identified potentially important differences 
between the sexes, with the 99th centile (upper refer-
ence limit) being twofold higher in men than in 
women.11 12 Whether the use of a single diagnostic 
threshold with contemporary assays has contributed to 
the under-diagnosis of myocardial infarction in women 
is unknown.
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WhAt Is AlreAdy knoWn on thIs topIc
Major differences exist in the diagnosis, management, and outcomes of men and 
women with acute coronary syndromes
High sensitivity cardiac troponin assays have identified differences in the reference 
range for troponin between men and women
Single diagnostic thresholds may lead to under-diagnosis of myocardial infarction 
in women and contribute to sex inequalities in treatment and outcomes
WhAt thIs study Adds
Use of a high sensitivity cardiac troponin I assay with sex specific diagnostic 
thresholds may double the diagnosis of myocardial infarction in women, such that 
the proportion of men and women diagnosed as having myocardial infarction would 
be similar
Women with small undisclosed increases in troponin concentrations only 
discernible using the high sensitivity assay and sex specific diagnostic threshold, 
were less likely to receive evidence based treatments and had increased rates of 
recurrent myocardial infarction and death at 12 months
Whether implementation of high sensitivity troponin assays and use of sex specific 
diagnostic thresholds will improve outcomes through better targeting of treatments 
for coronary heart disease requires urgent attention
 open access
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We evaluated the effect of a high sensitivity assay for 
cardiac troponin I using sex specific diagnostic thresh-
olds on the incidence of myocardial infarction. Using 
these new thresholds, we also compared the clinical 
characteristics and outcomes of patients with a diagno-
sis of myocardial infarction.
Methods
study population
We prospectively identified consecutive patients pre-
senting to the Royal Infirmary of Edinburgh, United 
Kingdom, from 1 August to 31 October 2012, in whom the 
attending doctor suspected an acute coronary syn-
drome. Patients not resident in the south east of Scot-
land were excluded from the study. We obtained 
information about the patients and their clinical out-
comes through the TrakCare software application (Inter-
Systems, Cambridge, MA) as previously described.9 10
Serum troponin concentrations were measured on 
admission and repeated six or 12 hours after the onset of 
symptoms13 14 using both a contemporary sensitive tro-
ponin I assay and a high sensitivity troponin I assay. 
Clinical decisions were based on the results of the con-
temporary assay only, with clinicians blinded to the 
results of the high sensitivity assay.
troponin assays
The ARCHITECTSTAT troponin I assay (Abbott Laborato-
ries, Abbott Park, IL) is a contemporary sensitive assay 
that has been validated in our institution.9 10 According 
to the manufacturer, the limit of detection is 10 ng/L 
and the upper reference limit (99th centile) of a normal 
reference population is 28 ng/L. Under local laboratory 
conditions the interassay coefficient of variation is less 
than 10% at 50 ng/L, and this concentration is used as 
the diagnostic threshold. The diagnostic threshold 
(50 ng/L) for the contemporary assay was based on a 
standard assessment of precision using pooled serum 
at a range of low concentrations across multiple plat-
forms and reagent lots. This was the lowest concentra-
tion that consistently provided a coefficient of variation 
of 10% or less.9 10
The ARCHITECTSTAT high sensitive troponin I assay 
(Abbott Laboratories, Abbott Park, IL) has a limit of 
detection of 1.2 ng/L and an interassay coefficient of 
variation of less than 10% at 4.7 ng/L. The upper refer-
ence limit (99th centile) based on 4590 samples from 
healthy men and women was determined by the manu-
facturer as 26 ng/L, and was twofold higher in men 
(34 ng/L) than in women (16 ng/L; see supplementary 
figure S1). These upper reference limits are consistent 
with other studies involving different ethnic groups.12 15 
An assessment of assay precision was performed 
locally, with our laboratories consistently able to 
achieve a coefficient of variation of less than 10% at 
6 ng/L in pooled serum.16
Diagnosis of myocardial infarction
The initial adjudication was undertaken using the peak 
troponin concentration from the contemporary assay 
while blinded to the high sensitivity troponin assay (fig 1). 
Where serial samples were available, we used peak and 
change in troponin concentration. Two cardiologists 
(ASVS, ALH) independently reviewed all clinical infor-
mation, including non-invasive and invasive investiga-
tions and outcomes from admission to 30 days. Patients 
were classified as having type 1 myocardial infarction, 
type 2 myocardial infarction, myocardial injury, or 
unstable angina.6 17 We defined type 1 myocardial 
infarction as myocardial necrosis in the context of an 
isolated presentation with suspected acute coronary 
syndrome with chest pain or evidence of myocardial 
ischaemia on the electrocardiogram. Patients with 
symptoms or signs of myocardial ischaemia as a result 
of increased oxygen demand or decreased supply (for 
example, tachyarrhythmia, hypotension, or anaemia) 
and myocardial necrosis were classified as having type 
2 myocardial infarction. Myocardial injury was defined 
as evidence of myocardial necrosis in the absence of 
any clinical features of myocardial ischaemia.6 Unsta-
ble angina was defined as symptoms or signs of myocar-
dial ischaemia in the absence of myocardial necrosis 
with evidence of myocardial ischaemia on resting elec-
trocardiography or stress testing, or obstructive coro-
nary artery disease on coronary angiography, or where 
the patient had a recurrent myocardial infarction or 
died within 30 days. Any discrepancies in adjudication 
were resolved by consensus between the two cardiolo-
gists through in-depth review of source documents. 
They then reclassified patients using troponin concen-
trations from the high sensitivity assay with both a sin-
gle generic threshold (26 ng/L) and sex specific 
thresholds (34 ng/L for men and 16 ng/L for women).
Follow-up
Subsequent readmission with myocardial infarction or 
death from any cause was recorded at 12 months. We 
used regional and national registries to ensure that fol-
low-up was complete for the entire study population. 
TrakCare software application (InterSystems, Cam-
bridge, MA) is a regional electronic patient record sys-
tem, which provides data on all hospital admissions to 
both tertiary and secondary care hospitals in south east 
Scotland. Through requests for data from the National 
Records of Scotland we identified deaths occurring any-
where in the United Kingdom. We used these two sources 
to record all admissions to secondary and tertiary hospi-
tals in our region and all deaths in the United Kingdom.18
statistical analysis
We compared continuous variables using Students t 
and Mann Whitney U tests as appropriate. For categori-
cal data we used the χ2 test for between group compari-
sons and McNemar’s test for within group comparisons. 
The kappa statistic was used to assess agreement for 
the adjudicated diagnosis between the two indepen-
dent adjudicators and was excellent (= κ 0.97, 95% con-
fidence interval 0.96 to 0.98).
Comparing diagnostic accuracy between two tropo-
nin assays in the absence of an independent reference 
standard is methodologically challenging.19 We used a 
modification of the method recommended by Glasziou 
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and colleagues.19 This involves comparing four groups 
classified as normal (no myocardial infarction) or dis-
eased (myocardial infarction) based on the contempo-
rary sensitive and high sensitivity assay (respectively, 
normal/normal—group 1, disease/disease—group 3, 
normal/disease—group 2, and disease/normal—group 
4) with the particular focus on comparing those with 
discrepant classifications (normal/disease—group 2 
and disease/normal—group 4).19 For this comparison, a 
variable that is related to the condition, however imper-
fectly, but is independent of the assay result (condi-
tional on the true unobserved disease state) is 
recommended. For example, evidence of myocardial 
ischaemia on electrocardiography could be used as 
such an “umpire test” wherein the discrepant group 
with the highest prevalence of ischaemia on electrocar-
diography would indicate the superior test. Conse-
quently we compared a range of risk factor, clinical and 
outcome variables for all groups, which are likely to be 
independent of the assay under consideration but are 
conditional on the true disease state. To make a global 
comparison for these variables, we performed a 
weighted summation of the selected variables for all 
patients in each group, where the weighting of each 
variable was determined by its association with the dis-
ease/disease group. We generated logistic regression 
models of myocardial infarction (group 3 versus group 
1, excluding group 2 and group 4 patients) on baseline 
clinical characteristics and outcomes (age, hyperten-
sion, hyperlipidaemia, diabetes, vascular disease, pre-
vious coronary revascularisation, presentation with 
chest pain, smoking status, electrocardiographic find-
ings on admission, drugs on admission, Killip class, 
and outcomes at 12 months). To calculate the probabil-
ity of myocardial infarction (disease/disease) for 
patients in all groups we used a parsimonious model 
(derived through backward selection). We used kernel 
density estimates to plot the frequency distribution of 
these estimates for each group.20
We modelled death or recurrent myocardial infarc-
tion using logistic regression with adjustment for age, 
renal function, and comorbidity, where group 1 (nor-
mal/normal) was the referent. Analyses were performed 
in SPSS Version 20.0.0 (Armonk, NY: IBM, USA, 2012) 
and R Version 3.0.0.
results
A total of 1126 consecutive patients with suspected 
acute coronary syndrome (mean age 66 years (SD 16 
years), 504 (45%) women and 622 (55%) men) were 
identified (Table 1).
Women with acute coronary syndrome were older 
than men with acute coronary syndrome (75 (SD 13) 
years v 67 (SD 14) years), had similar cardiovascular risk 
factors but were at higher risk of mortality (GRACE score 
130 (SD 32) v 114 (SD 30), P < 0.001)21 and less likely to 
have previously undergone coronary revascularisation. 
Women were as likely as men to present with chest pain 
(82% v 86%, P = 0.441) and to have ST segment depres-
sion and T wave inversion on electrocardiograms but 
less likely to present with ST segment elevation (19% v 
31%, P = 0.024). Compared with men, women on admis-
sion had lower serum troponin concentrations (29 ng/L 
(interquartile range 17–102) v 69 (22–480) ng/L, 
P = 0.025) and peak troponin concentrations (50 (24–
2630) ng/L v 1230 (82–14 700) ng/L, P < 0.001).
Diagnosis of myocardial infarction
Using the contemporary troponin I assay with a thresh-
old of 50 ng/L, 55 women (11%) and 117 men (19%) were 
classified as having type 1 myocardial infarction (figs 1 
and 2). Using a high sensitivity assay, the number of 
women classified as having type 1 myocardial infarction 
increased to 80 (16%) with the generic (26 ng/L) thresh-
old and to 111 (22%) with the sex specific (women 
16 ng/L) threshold (P < 0.001, figs 1 and 2 and supple-
mentary table S1). In contrast, in men the diagnosis of 
type 1 myocardial infarction using the high sensitivity 
assay increased only slightly to 142 (23%) with the 
generic (26 ng/L) threshold and to 131 (21%) with the 
sex specific (men 34 ng/L) threshold (P < 0.021).
Overall, 20 women (4%) and 27 men (4%) received an 
adjudicated diagnosis of type 2 myocardial infarction 
using the contemporary troponin I assay with a thresh-
old of 50 ng/L, and a further 15 women (3%) and 12 men 
(2%) had a diagnosis of myocardial injury (figs 1 and 2). 
Use of the high sensitivity assay and sex specific thresh-
olds resulted in a small but significant increase in the 
number of women with a diagnosis of type 2 myocardial 
infarction or myocardial injury.
Women (n=504; 45%)Men (n=622; 55%)
Suspected acute coronary syndrome (n=1126)
Adjudicated diagnosis using contemporary troponin I assay (single threshold)
(n=55; 11%)
(n=20; 4%)
(n=15; 3%)
(n=11; 2%)
(n=403; 80%)
Type 1 myocardial infarction
Type 2 myocardial infarction
Myocardial injury
Unstable angina
Others
Type 1 myocardial infarction
Type 2 myocardial infarction
Myocardial injury
Unstable angina
Others
Type 1 myocardial infarction
Type 2 myocardial infarction
Myocardial injury
Unstable angina
Others
(n=117; 19%)
(n=27; 4%)
(n=12; 2%)
(n=27; 4%)
(n=439; 71%)
Reclassication using high sensitivity troponin I assay (single threshold)
(n=80; 16%)
(n=25; 5%)
(n=23; 5%)
(n=8; 2%)
(n=368; 73%)
(n=142; 23%)
(n=30; 5%)
(n=15; 2%)
(n=20; 3%)
(n=415; 67%)
Reclassication using high sensitivity troponin I assay (sex specic threshold)
(n=111; 22%)
(n=280; 6%)
(n=28; 6%)
(n=6; 1%)
(n=331; 66%)
(n=131; 21%)
(n=28; 5%)
(n=12; 2%)
(n=22; 4%)
(n=429; 69%)
Fig 1 | steps involved in adjudication and classification of patients with suspected acute 
coronary syndrome. Patients were adjudicated using the contemporary troponin i assay 
with a single threshold (50 ng/l) and then reclassified using the high sensitivity troponin i 
assay, with both single (26 ng/l) and sex specific (men 34 ng/l and women 16 ng/l) 
thresholds
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Diagnostic accuracy
Patients were stratified into groups using both assays: 
those with no myocardial infarction (group 1), those 
with myocardial infarction (group 3) where the assays 
were concordant, and those identified as having myo-
cardial infarction only using the high sensitivity assay 
with sex specific thresholds (group 2, Table 2). No 
patients were identified as having myocardial infarction 
by the contemporary assay but not the high sensitivity 
assay (group 4). Patients in groups 2 and 3 had similar 
clinical characteristics and changes on electrocardio-
grams but differed from those patients without myocar-
dial infarction (group 1; see supplementary tables S2 
and S3). Age, chest pain, known vascular disease, myo-
cardial ischaemia on the electrocardiogram, creatinine 
concentration, and death or recurrent myocardial 
infarction at one year were independently associated 
with a diagnosis of myocardial infarction on the index 
admission (C statistic 0.77, 95% confidence interval 0.72 
to 0.82, likelihood ratio statistic 50.6, df = 6, P < 0.001) 
based on patients in group 1 and group 3. When this 
model was used to estimate the probability of myocar-
dial infarction in all groups, those with discordant 
assay results in group 2 were similar to patients in group 
3 but differed from those in group 1 (fig 3).
Management of men and women with myocardial 
infarction
Women with a diagnosis of myocardial infarction 
(group 3) were less likely than men with myocardial 
infarction to be referred to a cardiologist (80% v 95%, 
P = 0.004), undergo coronary angiography (47% v 74%, 
P = 0.001) or percutaneous coronary revascularisation 
(29% v 64%, P < 0.001), or be prescribed statin treat-
ment on discharge (60% v 85%, P = 0.001; Table 3). Dif-
ferences persisted in our sensitivity analyses stratified 
table 1 | baseline characteristics of men and women with suspected acute coronary syndrome. values are numbers (percentages) unless stated 
otherwise
characteristics suspected acute coronary syndrome acute coronary syndrome*
all (n = 1126) Women (n = 504) Men (n = 622) Women (n = 117) Men (n = 153) P value†
Mean (SD) age (years) 66 (16) 69 (16) 63 (15) 75 (13) 67 (14) <0.001
Chest pain 936 (83) 405 (81) 531 (85) 96 (82) 130 (86) 0.441
Risk factors:
 Smoker 277 (27) 79 (17) 198 (34) 20 (19) 47 (33) 0.012
 Hypertension 596 (53) 271 (54) 325 (52) 71 (61) 83 (55) 0.348
 Hyperlipidaemia 503 (45) 210 (42) 293 (47) 53 (45) 80 (53) 0.212
 Diabetes mellitus 184 (16) 72 (14) 112 (18) 22 (19) 33 (22) 0.540
Medical history:
 Ischaemic heart disease 466 (42) 193 (38) 273 (44) 56 (48) 81 (54) 0.348
 Myocardial infarction 292 (26) 105 (21) 187 (30) 37 (32) 55 (36) 0.412
 Ischaemic stroke 93 (8) 39 (8) 54 (9) 13 (11) 13 (9) 0.493
 Transient ischaemic attack 54 (5) 28 (6) 26 (4) 4 (3) 3 (2) 0.466
 Peripheral vascular disease 27 (2) 5 (1) 22 (4) 3 (3) 10 (7) 0.157
Revascularisation:
 Previous PCI 166 (15) 50 (10) 116 (19) 14 (12) 33 (22) 0.033
 Previous CABG 86 (8) 21 (4) 65 (10) 7 (6) 22 (15) 0.025
Haemodynamics:
 Mean (SD) systolic pressure (mm Hg) 135 (25) 138 (27) 133 (23) 138 (30) 131 (22) 0.057
 Mean (SD) diastolic pressure (mm Hg) 73 (15) 71 (15) 73 (15) 73 (17) 73 (14) 0.816
 Heart rate (beats/min) 80 (21) 81 (22) 79 (20) 83 (19) 79 (21) 0.226
Clinical chemistry:
 Mean (SD) haemoglobin (g/L) 134 (35) 128 (47) 139 (19) 126 (16) 138 (21) <0.001
 Mean (SD) creatinine (Âµmol/L) 87 (53) 79 (34) 93 (63) 91 (43) 103 (78) 0.153
 Mean (SD) urea nitrogen (mmol/L) 7 (5) 7 (6) 6 (4) 8 (6) 7 (3) 0.119
 Mean (SD) cholesterol (mmol/L) 4 (1) 5 (1) 5 (2) 5 (1) 5 (1) 0.115
 Median (interquartile range) admission troponin I (ng/L) 6 (2–24) 6 (2–20) 7 (3–28) 29 (17–102) 69 (22–480) 0.025
 Median (interquartile range) peak troponin I (ng/L) 7 (3–34) 6 (2–27) 8 (3–53) 50 (24–2630) 1230 (82–14 700) <0.001
Electrocardiography:
 ST elevation 118 (11) 35 (7) 83 (14) 22 (19) 47 (31) 0.024
 ST depression 106 (10) 59 (12) 47 (8) 24 (21) 32 (21) 0.920
 T wave inversion 221 (20) 100 (21) 121 (20) 28 (24) 40 (26) 0.662
Drugs on admission:
 Aspirin 432 (39) 180 (36) 252 (41) 53 (46) 71 (48) 0.801
 Clopidogrel 133 (12) 57 (11) 76 (13) 14 (12) 23 (15) 0.466
 β blockers 319 (29) 143 (29) 176 (29) 40 (35) 52 (35) 0.984
 ACE inhibitors 366 (33) 159 (32) 207 (34) 47 (41) 48 (32) 0.158
 Statins 469 (42) 196 (39) 273 (45) 55 (48) 76 (51) 0.608
PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; ACE = angiotensin converting enzyme.
*Baseline characteristics are provided for all patients with acute coronary syndrome (type 1 myocardial infarction or unstable angina) following reclassification using the high sensitivity assay 
with sex specific diagnostic thresholds.
†Comparison between men and women with diagnosis of acute coronary syndrome.
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by age and restricted to patients with non-ST segment 
elevation myocardial infarction (data not shown). Of 
those patients who underwent coronary angiography, 
the proportion of women and men with normal coro-
nary arteries (14% v 5%) and with single vessel (31% v 
42%), two vessel (14% v 23%), and three vessel (42% v 
29%) disease did not differ significantly (P = 0.123 over-
all). Women identified as having myocardial infarction 
using only the high sensitivity assay with sex specific 
thresholds (group 2) were least likely to undergo inves-
tigations and treatment for myocardial infarction.
clinical outcomes of men and women with 
myocardial infarction
Women with myocardial infarction identified using the 
high sensitivity assay with sex specific thresholds 
(group 2) or using both assays (group 3) had the highest 
risk of death or recurrent myocardial infarction at 12 
months compared with those without myocardial infarc-
tion (group 1): 25% v 24% v 4%, respectively (P < 0.001; 
table 3 and fig 4). Similar patterns were observed for 
men in groups 2 and 3 compared with men in group 1: 
36% v 19% v 8%, respectively (P < 0.001; table 3 and fig 
4). After adjustment for age, renal function, and history 
of diabetes, women in groups 2 and 3 were at increased 
risk of death or recurrent myocardial infarction com-
pared with women in group 1 (odds ratio 6.0, 95% confi-
dence interval 2.5 to 14.4 and 5.8, 2.3 to 14.2, respectively, 
P < 0.001 for both). Similarly, men in groups 2 and 3 
were at increased risk of death or recurrent myocardial 
infarction compared with men in group 1 (5.3, 1.5 to 19.9, 
P = 0.012, and 2.1, 1.1 to 3.8, P = 0.021, respectively).
We further evaluated outcomes in women, compar-
ing the generic threshold (26 ng/L) with the sex specific 
threshold (16 ng/L) and obtained similar results. The 
event rate in women with troponin concentrations of 
17–26 ng/L was sixfold higher (23%) than those in 
women with troponin concentrations of 16 ng/L or less 
(4%) and similar to women with troponin concentra-
tions of 27–49 ng/L (25%, P for trend <0.001), suggest-
ing that the use of sex specific thresholds will correctly 
identify more women at increased risk of recurrent myo-
cardial infarction or death than a generic threshold.
discussion
Major differences exist in the diagnosis and manage-
ment of myocardial infarction in men and women pre-
senting with suspected acute coronary syndrome. Our 
findings using a high sensitivity troponin assay sug-
gest that the use of contemporary assays with a single 
diagnostic threshold disproportionately under-diag-
nose myocardial infarction in women and contribute 
to sex inequalities in treatments and outcomes.
We make several novel and important observations. 
Firstly, we currently diagnose twice as many men with 
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table 2 | 2×2 tables comparing high sensitivity cardiac troponin assay (sex specific 
thresholds) with contemporary assay for diagnosis of type 1 myocardial infarction in men 
and women*
contemporary assay (single threshold)
negative Positive total
High sensitivity assay 
(sex specific threshold)
Women:
 Negative Group 1: 337 Group 4: 0 337
 Positive Group 2: 56 Group 3: 55 111
Total 393 55 448
Men:
 Negative Group 1: 451 Group 4: 0 451
 Positive Group 2: 14 Group 3: 117 131
Total 465 117 582
*Patients were stratified into groups using both assays: those with no myocardial infarction (group 1) and 
myocardial infarction (group 3) where the assays were concordant and for those reclassified as having 
myocardial infarction using the high sensitivity assay with sex specific thresholds (group 2). There were no 
patients in whom troponin concentrations were below the threshold of the high sensitivity assay, but were above 
the threshold on the contemporary assay (group 4).
Probability of myocardial infarction
D
en
si
ty
0
2
3
4
5
6
1
0 0.25 0.50 0.75 1.00
Group 1 (no myocardial infarction)
Group 2 (reclassied)
Group 3 (myocardial infarction)
Fig 3 | Density plots of predicted probabilities of 
myocardial infarction in women. Women were stratified 
into three groups using both assays: those with no 
myocardial infarction (group 1; solid blue line) and 
myocardial infarction (group 3; dashed green line) where 
the assays were concordant and those reclassified as 
having myocardial infarction using the high sensitivity 
assay with sex specific thresholds (group 2; dashed red 
line). rug plot indicates the probability of myocardial 
infarction for individual patients in group 2 (red lines) and 
group 3 (green lines)
Fig 2 | Proportion of men 
and women with diagnosis 
of type 1 myocardial 
infarction and type 2 
myocardial infarction or 
myocardial injury using the 
contemporary troponin i 
assay (single threshold 
50 ng/l) and high 
sensitivity troponin i assay 
(single threshold 26 ng/l, 
and sex specific threshold 
34 ng/l for men and 
16 ng/l for women)
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myocardial infarction as we do women. In patients with 
suspected acute coronary syndrome, use of a high sen-
sitivity troponin assay with sex specific diagnostic 
thresholds doubles the diagnosis of myocardial infarc-
tion in women, such that the proportion of men and 
women with a diagnosis of myocardial infarction is now 
similar. Secondly, women identified as having myocar-
dial infarction using only the high sensitivity assay with 
sex specific diagnostic thresholds had similar clinical 
characteristics and prognosis to those women diag-
nosed as having myocardial infarction using the con-
temporary assay. Thirdly, women are less likely than 
men to be referred to a cardiologist, to undergo coro-
nary angiography or revascularisation, or to receive sec-
ondary prevention. These inequalities were most 
pronounced in those women with myocardial infarction 
who were not identified by the contemporary assay. 
Finally, women only identified using the high sensitiv-
ity assay with sex specific thresholds had the highest 
risk of death or recurrent myocardial infarction suggest-
ing that these women have the greatest potential to ben-
efit from reclassification and provision of treatment for 
acute myocardial infarction.
In patients with suspected acute coronary syndrome, 
why should the proportion of men and women diag-
nosed as having myocardial infarction differ? Men were 
twice as likely as women to have a diagnosis of myocar-
dial infarction using a single threshold with our con-
temporary assay. This sex difference has been observed 
in other major clinical trials.8 22 Historically this appar-
ent under-diagnosis has been attributed to differences 
in presentation, with women more likely to have atypi-
cal symptoms and less reliable electrocardiographic 
changes.5 However, others4 and we have found that the 
same proportion of men and women reported chest 
pain and had electrocardiographic changes. Our find-
ings suggest an additional explanation for the under-di-
agnosis of myocardial infarction in women: the use of 
inappropriate diagnostic thresholds. This then leads to 
the question of why women have lower troponin con-
centrations than men. Cardiac troponin concentrations 
correlate with left ventricular mass,23 24 and women 
have less left ventricular mass than men.25 It is therefore 
not surprising that sex specific differences exist in the 
table 3 | Management and outcome of patients with and without myocardial infarction. † values are numbers (percentages) unless stated otherwise
Women Men
group 1: no 
myocardial 
infarction 
(n = 337)
group 2: 
reclassified 
(n = 56)
group 3: 
myocardial 
infarction 
(n = 55) P value
group 1: no 
myocardial 
infarction 
(n = 451)
group 2: 
reclassified 
(n = 14)
group 3: 
myocardial 
infarction 
(n = 117) P value
Investigations:
 Cardiology referral 51 (15) 11 (20) 43 (80) <0.001 84 (19) 5 (36) 111 (95)* <0.001
 Exercise tolerance test 6 (2) 1 (2) 0 (0) 0.606 16 (4) 0 (0) 1 (1) 0.233
 Echocardiography 16 (5) 5 (9) 25 (46) <0.001 20 (4) 0 (0) 38 (32) <0.001
 Coronary angiography 10 (3) 1 (2) 26 (47) <0.001 21 (5) 3 (21)* 87 (74)* <0.001
Revascularisation:
 PCI 5 (2) 0 (0) 16 (29) <0.001 11 (2) 3 (21)* 75 (64)* <0.001
Drugs on discharge:
 Aspirin 117 (35) 29 (57) 44 (85) <0.001 185 (42) 10 (71) 95 (85) <0.001
 Clopidogrel 41 (12) 9 (18) 39 (75) <0.001 62 (14) 8 (57)* 91 (81) <0.001
 β blockers 81 (24) 23 (45) 25 (48) <0.001 130 (29) 9 (64) 61 (54) <0.001
 ACE inhibitors 90 (27) 19 (37) 31 (60) <0.001 153 (35)* 5 (36) 81 (72) <0.001
 Statins 130 (39) 30 (59) 31 (60) 0.001 196 (45) 9 (64) 95 (85)* <0.001
 Outcome at 12 months
 Reinfarction or death 12 (4) 14 (25) 13 (24) <0.001‡ 35 (8) 5 (36) 22 (19) 0.001‡
PCI = percutaneous coronary intervention; ACE = angiotensin converting enzyme.
Patients with increased troponin concentrations classified as either type 2 myocardial infarction or myocardial injury are not included.
*P < 0.05 (comparing men and women).
†Men and women were stratified into three groups using both assays: those with no myocardial infarction (group 1) and myocardial infarction (group 3) where the assays were concordant and 
for those reclassified as having myocardial infarction using the high sensitivity assay with sex specific thresholds (group 2).
‡Derived from log rank test.
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Fig 4 | survival free from 
death or recurrent 
myocardial infarction in 
women and men with 
suspected acute coronary 
syndrome. Outcomes are 
shown for women and men 
with no myocardial 
infarction (group 1, solid 
blue line) and with 
myocardial infarction 
(group 3, dashed green 
line) where both assays 
were concordant, and for 
those reclassified as having 
myocardial infarction using 
the high sensitivity assay 
with sex specific thresholds 
(group 2, dashed red line)
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normal reference range for troponin and have been 
observed for other cardiac biomarkers, such as creatine 
kinase.26 However, to date contemporary assays have 
not had the sensitivity and precision to quantify tropo-
nin in more than 90% of healthy people and therefore 
were unable to determine sex specific upper reference 
limits.12 Our findings show that contemporary troponin 
assays with a single diagnostic threshold have dispro-
portionately disadvantaged women and contributed to 
under-diagnosis of myocardial infarction.
The universal definition of myocardial infarction rec-
ognises that reference values may differ for high sensi-
tivity troponin assays in men and women. These assays 
are widely available for clinical use outside the United 
States and are now recommended for the assessment 
of patients with suspected acute coronary syndrome 
by the National Institute for Health and Care Excel-
lence in the United Kingdom.27 Importantly, although 
guidelines note that differences exist between the 
sexes in the reference range for troponin, no explicit 
recommendations on their use have been made owing 
to insufficient evidence. Our observations provide the 
first evaluation of the use of sex specific diagnostic 
thresholds for myocardial infarction. Although 
improvement in the diagnosis of type 1 myocardial 
infarction is likely to be beneficial, concerns have been 
raised about the potential for high sensitivity assays to 
reduce clinical specificity.28–30 In our cohort, second-
ary causes of myocardial injury and infarction were 
present in only a few patients but were more common 
in women than in men. Specificity was unchanged in 
men and only slightly lower in women suggesting that 
noticeable improvements in diagnostic sensitivity will 
not be offset by reductions in specificity.
We observed major sex differences in the manage-
ment of myocardial infarction: less than half of women 
with an adjudicated diagnosis of myocardial infarction 
received optimal treatment compared with most men. 
Our findings are consistent with previous observations 
highlighting sex inequalities in the provision of health-
care to patients with myocardial infarction.31–33 While 
we believe that inappropriate single diagnostic thresh-
olds contribute to these inequalities, differences in the 
age and clinical presentation of men and women may 
also be important. We therefore undertook sensitivity 
analyses stratified by age and ST segment elevation and 
found that inequalities persisted between men and 
women, suggesting that the use of inappropriate diag-
nostic thresholds is a major contributing factor.
Women are at higher short term and long term risk of 
death after acute coronary syndrome.2 32 34 35 When a 
previous generation assay was used, women with sus-
pected acute coronary syndrome were less likely to have 
increased plasma troponin concentrations,5 36 and this 
may explain why clinicians were perhaps less likely to 
initiate evidence based treatments or to consider revas-
cularisation. In our study, women with small undis-
closed increases in troponin concentrations that were 
only discernible using the high sensitivity assay with 
sex specific diagnostic thresholds, were less likely to 
receive evidence based treatments and had the highest 
rates of reinfarction and death at 12 months. We have 
previously shown that lowering the diagnostic thresh-
old of a contemporary assay for myocardial infarction 
increased the provision of treatment and was associ-
ated with a reduction in recurrent myocardial infarction 
and death.9 It is perhaps inevitable that further lower-
ing the diagnostic threshold will increase the number of 
patients with a diagnosis of myocardial infarction. 
Whether implementation of high sensitivity troponin 
assays and use of sex specific diagnostic thresholds will 
improve outcomes through better targeting of treat-
ments for coronary heart disease requires urgent atten-
tion and is the focus of an ongoing multicentre 
randomised controlled trial (clinical trials.gov 
NCT01852123).
limitations of this study
Our study has several limitations. Firstly, our cohort 
was derived from a single tertiary cardiac centre. How-
ever, we prospectively included all consecutive 
patients with no case selection and therefore believe 
our findings are both representative and generalisable. 
Secondly, we evaluated a single high sensitivity tropo-
nin I assay and diagnostic thresholds are likely to vary 
between different manufacturers and between tropo-
nin I and T assays.12 However, sex differences in the 
normal reference range have been observed across 
multiple  troponin assays, including contemporary and 
high  sensitivity methods.11 While only one in three lab-
oratories currently uses the 99th centile for the diagno-
sis of myocardial infarction,7 we acknowledge that the 
impact of implementing high sensitivity assays with 
sex specific thresholds may be less noticeable in cen-
tres that use lower diagnostic thresholds based on 
manufacturers’ rather than local laboratory measures 
of assay precision. Thirdly, we accept that some 
patients with increased troponin concentrations may 
be misclassified as having type 1 myocardial infarction 
using the high sensitivity assay. This is because many 
patients with undetectable troponin concentrations 
using the  contemporary assay were reassured and dis-
charged without investigation such as coronary angi-
ography or cardiac magnetic resonance imaging. 
However, our study reflects real world clinical practice 
and this approach to the diagnosis of myocardial 
infarction is consistent with major contemporary clini-
cal trials,37 has been advocated in recent studies evalu-
ating diagnostic accuracy of troponin assays,8 22 and 
clearly identifies those patients at highest risk who are 
likely to benefit most from treatment for myocardial 
infarction.
conclusion
Coronary heart disease remains the leading cause of 
mortality in women. Our findings suggest that differ-
ences in outcome between men and women are only in 
part due to sex differences in the clinical presentation of 
coronary artery disease. We show that myocardial 
infarction is under-diagnosed in women and that this 
contributes to inequalities in the management and 
treatment of myocardial infarction.
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